Walter Moos

Oncologic, Inc. develops patented technology for cancer treatment. The company was founded in January, 2000 by George Mayers, Sam Rose, Henry Rapoport & David S. Rose and is headquartered in Berkeley, CA

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

SRI International provides contract research and development services. It is an independent, nonprofit research institute conducting client-sponsored research and development for government agencies, commercial businesses, foundations, and other organizations. The company was founded in 1946 and is headquartered in Menlo Park, CA.

Mimotopes Pty Ltd is an industry leader in the peptide and discovery chemistry sector. Mimotopes develops, markets and distributes high quality biochemical products and services for the life-science sector. Their customers range from small labs and universities worldwide, to large multinational drug discovery companies. Their core competence covers the following areas: ' Custom Peptides Mimotopes' custom peptides are synthesized in modern, automated synthesizers using advanced solid phase techniques. The value in using Mimotopes custom peptides is not only that they offer a wide range of peptide lengths, purities and quantities. Their customers can also draw on the exceptional experience of their technical staff, who consult with them to design the peptide application that gives the best possible research outcome. ' PepSets Peptide Libraries Peptide libraries for various screening applications in Proteomics, Immunology and Drug Discovery. PepSets peptide libraries provide researchers with a rapid and cost effective solution for an immense range of bioactivity screening purposes. These sets of custom synthesized peptides enable fast, efficient results. ' Peptide Reagents High-quality amino acids and peptide synthesis reagents. The same reagents that Mimotopes uses in its in-house production system. ' SynPhase Lanterns Modular solid phase supports for organic synthesis, combinatorial chemistry, peptide chemistry, molecule scavenging and affinity applications. Convenient to handle, SynPhase Lanterns are the unique and reliable alternative to using conventional resins for solid-phase synthetic chemistry. Not only do SynPhase Lanterns provide superior reaction kinetics, but their unrivalled ease of handling results in less errors, better traceability and ultimately, faster, more accurate results.

Axiom Biotechnologies, Inc. discovered and developed drugs through use of its proprietary human cell-based physiogenomics technology and focused on cancer, acid reflux disease, and obesity. The company was headquartered in San Diego, CA.

Red Abbey Venture Partners LLC (Red Abbey Venture Partners) is a venture capital firm subsidiary of Red Abbey LLC founded in 2004 by Philip Goelet, W. Matthew Zuga, and Frank Adair Bonsal. The firm is headquartered in Baltimore, Maryland.

Keystone Symposia operates as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops. The company was founded by C. Fred Fox in 1972 and is headquartered in Silverthorne, CO.

Critical Path Institute is a nonprofit organization established in 2005 as a public and private partnership with the FDA's Critical Path Initiative program. The non-profit company is based in Tucson, AZ, and operates from Ireland with additional staff in multiple other locations. The company's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. The company orchestrates the development of drug development tools through an innovative, collaborative approach to the sharing of data and expertise, and accelerate the pace and reduce the costs of medical product development by building consensus among the participating institutions. The company was founded in 2005 by Raymond L. Woosley, Glenn C. Rice. Daniel M. Jorgensen has been the CEO of the company since 2022.

Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA.

Alnis Biosciences, Inc. is a biopharmaceutical company that develops therapeutics from its nanoparticle technology platform. The company was founded on May 29, 2007 and is headquartered in Raleigh, NC.

Circle Pharma, Inc. provides biotechnology services. The company was founded by Matthew P. Jacobson and Scott Lokey in June 2014 and is headquartered in San Francisco, CA.

ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California.

Valitor, Inc. develops a new generation of biotechnology drugs. It develops methods of modifying therapeutic proteins to achieve substantial control over pharmacokinetics, target specificity and bioactivity. The company was founded by Kevin E. Healy, Wesley M. Jackson and David Schaffer in 2010 and is headquartered in Berkeley, CA.

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.